The global Lyme disease testing market size was estimated to be USD 11.76 billion in 2023 and is expected to reach USD 28.05 billion by 2034 with a CAGR of 8.22% during the forecast period 2024-2034. The market will grow as a result of the following factors: rising incidence of Lyme disease, improvements in diagnostic technologies, a greater emphasis on early diagnosis and treatment, rising public awareness, government initiatives, and strategic alliances and collaborations.
Strategic collaborations and partnerships play a crucial role in driving market growth by enabling companies to leverage each other's strengths and resources to foster innovation and expand their market reach. These alliances allow businesses to enhance their service offerings and better meet customer needs, creating competitive advantages that are difficult to replicate independently. For instance, in April 2023, Abbott Laboratories announced its collaboration with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which consists of over 100 global scientists aiming to assess and mitigate the impact of climate change on disease outbreaks through data science and diagnostic testing.
By diagnostic test, the serological tests segment accounted for the highest revenue-grossing segment in the global Lyme disease testing market in 2023 owing to the widespread use of ELISA (enzyme-linked immunosorbent assay) and Western Blot tests as standard methods for detecting Lyme disease antibodies, which are highly trusted by healthcare providers. For instance, in September 2024, Aces Diagnostics Inc. and Focus on Lyme revealed a breakthrough in the diagnosis of Lyme disease with a new test that has an accuracy of over 90% in detecting the disease at all phases, including the critical first 14 days post-infection. This test is being developed and manufactured by Aces Diagnostics, with the goal of obtaining FDA authorization to provide universal patient access. Additionally, the PCR tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for more precise, early-stage detection methods that identify the presence of Borrelia DNA in patient samples, offering higher accuracy and sensitivity.
By sample, the blood samples segment accounted for the highest revenue-grossing segment in the global Lyme disease testing market in 2023 owing to the ease of collection and widespread availability of blood-based diagnostic tests, which are commonly used for both serological and molecular testing. For instance, in November 2023, IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the imminent launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases such as canine leishmaniosis. The SNAP Leish 4Dx Test use the reputable SNAP 4Dx Plus testing technology, which can identify Lyme disease, heartworm illness, ehrlichiosis, and anaplasmosis. The SNAP Leish 4Dx Test promotes vector-borne disease diagnosis globally by substituting Lyme disease detection with detection of leishmaniosis, a more common endemic disease in several parts of the world. Additionally, the cerebrospinal fluid segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on diagnosing late-stage Lyme disease, which may involve neurological symptoms, requiring cerebrospinal fluid analysis for more comprehensive testing.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global Lyme disease testing market in 2023 owing to the availability of advanced diagnostic tools, skilled healthcare professionals, and the high patient influx for Lyme disease diagnosis and treatment. For instance, in December 2023, Quest Diagnostics announced a new confirmatory testing service for novel psychoactive substances (NPS). The new panel screens for 88 chemicals and covers a wide range of drug classes, including designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additions. Other illicit additives (xylazine) and fentanyl analogs (acetyl fentanyl) are two of the groups that are fast speeding up America's overdose epidemic. Additionally, the diagnostic laboratories segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend of outsourcing diagnostic testing to specialized labs, offering more advanced and varied testing methods with quicker turnaround times.
North American region is anticipated for the highest revenue share during the forecast period owing to the high prevalence of Lyme disease in countries like the U.S. and Canada, advanced healthcare infrastructure, widespread awareness of tick-borne diseases, and strong government initiatives supporting early diagnosis and treatment. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of Lyme disease, expanding healthcare infrastructure, rising healthcare investments, and the growing presence of diagnostic companies in emerging markets such as China and India. For instance, Virax Biolabs Group Limited announced today, April 27, 2024, at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) Congress in Barcelona, Spain, the launch of ImmuneSelect ("ImmuneSelect") within the ViraxImmuneTM T-Cell diagnostic platform for research-use-only ("RUO").
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Strategic collaborations and partnerships play a crucial role in driving market growth by enabling companies to leverage each other's strengths and resources to foster innovation and expand their market reach. These alliances allow businesses to enhance their service offerings and better meet customer needs, creating competitive advantages that are difficult to replicate independently. For instance, in April 2023, Abbott Laboratories announced its collaboration with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which consists of over 100 global scientists aiming to assess and mitigate the impact of climate change on disease outbreaks through data science and diagnostic testing.
By diagnostic test, the serological tests segment accounted for the highest revenue-grossing segment in the global Lyme disease testing market in 2023 owing to the widespread use of ELISA (enzyme-linked immunosorbent assay) and Western Blot tests as standard methods for detecting Lyme disease antibodies, which are highly trusted by healthcare providers. For instance, in September 2024, Aces Diagnostics Inc. and Focus on Lyme revealed a breakthrough in the diagnosis of Lyme disease with a new test that has an accuracy of over 90% in detecting the disease at all phases, including the critical first 14 days post-infection. This test is being developed and manufactured by Aces Diagnostics, with the goal of obtaining FDA authorization to provide universal patient access. Additionally, the PCR tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for more precise, early-stage detection methods that identify the presence of Borrelia DNA in patient samples, offering higher accuracy and sensitivity.
By sample, the blood samples segment accounted for the highest revenue-grossing segment in the global Lyme disease testing market in 2023 owing to the ease of collection and widespread availability of blood-based diagnostic tests, which are commonly used for both serological and molecular testing. For instance, in November 2023, IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the imminent launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases such as canine leishmaniosis. The SNAP Leish 4Dx Test use the reputable SNAP 4Dx Plus testing technology, which can identify Lyme disease, heartworm illness, ehrlichiosis, and anaplasmosis. The SNAP Leish 4Dx Test promotes vector-borne disease diagnosis globally by substituting Lyme disease detection with detection of leishmaniosis, a more common endemic disease in several parts of the world. Additionally, the cerebrospinal fluid segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on diagnosing late-stage Lyme disease, which may involve neurological symptoms, requiring cerebrospinal fluid analysis for more comprehensive testing.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global Lyme disease testing market in 2023 owing to the availability of advanced diagnostic tools, skilled healthcare professionals, and the high patient influx for Lyme disease diagnosis and treatment. For instance, in December 2023, Quest Diagnostics announced a new confirmatory testing service for novel psychoactive substances (NPS). The new panel screens for 88 chemicals and covers a wide range of drug classes, including designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additions. Other illicit additives (xylazine) and fentanyl analogs (acetyl fentanyl) are two of the groups that are fast speeding up America's overdose epidemic. Additionally, the diagnostic laboratories segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing trend of outsourcing diagnostic testing to specialized labs, offering more advanced and varied testing methods with quicker turnaround times.
North American region is anticipated for the highest revenue share during the forecast period owing to the high prevalence of Lyme disease in countries like the U.S. and Canada, advanced healthcare infrastructure, widespread awareness of tick-borne diseases, and strong government initiatives supporting early diagnosis and treatment. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness of Lyme disease, expanding healthcare infrastructure, rising healthcare investments, and the growing presence of diagnostic companies in emerging markets such as China and India. For instance, Virax Biolabs Group Limited announced today, April 27, 2024, at the European Society of Clinical Microbiology and Infectious Diseases Global 2024 (ESCMID) Congress in Barcelona, Spain, the launch of ImmuneSelect ("ImmuneSelect") within the ViraxImmuneTM T-Cell diagnostic platform for research-use-only ("RUO").
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Diagnostic Test, Sample, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Lyme Disease Testing Market Report 2023 - 2034
Lyme Disease Testing Market Analysis & Forecast by Diagnostic Test 2023 - 2034 (Revenue USD Bn)
- Serological Test
- Polymerase Chain Reaction (PCR) Test
- Culture Test
- Antigen Test
- Others
Lyme Disease Testing Market Analysis & Forecast by Sample 2023 - 2034 (Revenue USD Bn)
- Blood
- Cerebrospinal Fluid (CSF)
- Joint Fluid
- Urine
- Others
Lyme Disease Testing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Diagnostic Laboratories
- Clinics
- Research Institutes
- Others
Lyme Disease Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Lyme Disease Testing Market: Diagnostic Test Estimates & Trend Analysis
8. Lyme Disease Testing Market: Sample Estimates & Trend Analysis
9. Lyme Disease Testing Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Lyme Disease Testing Market
12. Europe Global Lyme Disease Testing Market
13. Asia Pacific Global Lyme Disease Testing Market
14. Latin America Global Lyme Disease Testing Market
15. MEA Global Lyme Disease Testing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- QIAGEN N.V.
- bioMérieux SA
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Zeus Scientific Inc.
- Abbott Laboratories
- PerkinElmer Inc.
- Bio-Rad Laboratories Inc.
- T2 Biosystems Inc.
- Oxford Immunotec Global PLC
- IGeneX Inc.
- DiaSorin S.p.A.
- Becton
- Dickinson and Company (BD)
- Luminex Corporation
- LabCorp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 11.76 Billion |
| Forecasted Market Value ( USD | $ 28.05 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
